Denemek ALTIN - Özgür
Immuno-Oncology Looks Set To Become The Fifth Pillar Of Cancer Treatment
Express Pharma
|October 1-15, 2017
-
IMMUNO-ONCOLOGY (IO) looks set to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments according to GlobalData, a recognised leader in providing business information and analytics.
The company’s health team analysed over 4,000 clinical trials and more than 800 IO products in Phase I–III clinical trials to generate a number of unique actionable insights in their latest report: 'Pharma Focus Visual Analysis of Immuno-Oncology Development and Opportunities'. The report predominantly focusses on developments in active immunotherapy products based on their molecular targets and molecule types. The team also assessed immune checkpoint modulators (based on 21 individual targets) together with a total of 18 solid tumour types and eight blood cancers.
Bu hikaye Express Pharma dergisinin October 1-15, 2017 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Express Pharma'den DAHA FAZLA HİKAYE
Express Pharma
Future opportunities in biologics and biosimilars will demand significant investment
Semaglutide's patent expiry in India in March 2026 has become the immediate trigger for the next wave of pharmaceutical development activity, but the larger opportunity goes well beyond semaglutide itself.
1 mins
April 2026
Express Pharma
Gandhi Automations elevates loading bay efficiency with advanced dock leveler solutions
Engineered systems from Gandhi Automations Pvt Ltd enhance safety, durability and seamless material flow
2 mins
April 2026
Express Pharma
Redefining humidity control in pharma manufacturing
Bry-Air systems reflect shift towards material-based humidity control in pharma manufacturing
2 mins
April 2026
Express Pharma
2026 amendments to NDCT Rules: Foreword to India's biosimilars story or a step too short?
Kosturi Ghosh, Partner, and Ajeya B G, Sr Associate, in the Corporate practice at Trilegal, assess India's 2026 NDCT amendments as a timely push for biosimilars, but not enough on their own. The article highlights that stronger policy clarity and ecosystem support will be critical to truly unlock growth.
4 mins
April 2026
Express Pharma
Optima advances digital twins to boost efficiency in pharmaceutical turnkey machines
Virtual testing, training and simulation tools enhance performance in complex manufacturing environments
7 mins
April 2026
Express Pharma
Complete environmental monitoring solution – testo Saveris Pharma
There are several critical applications in the industry like research and development that demand for continuous & reliable monitoring of important environmental parameters.
3 mins
April 2026
Express Pharma
Flexotherm heating tapes & cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
April 2026
Express Pharma
Safeguarding the pharma excipients supply chain
Adding excipient details to QR codes of the top 300 drugs may not be a tough task. But as CDSCO plans to expand QR codes to cover other critical drug categories in phases, all segments of the pharma value chain need to tighten their systems, analyses Viveka Roychowdhury
15 mins
April 2026
Express Pharma
This is only the beginning of a much larger global patent-cliff cycle
As the patent expiry of semaglutide is almost there in India, several Indian pharma firms are preparing to introduce generic versions, highlighting the sector's agility in responding to high-value loss-of-exclusivity opportunities.
1 min
April 2026
Express Pharma
Leading people in the age of Al
As Al reshapes pharma, HR leadership is being drawn into a deeper question that goes beyond technology to the future of people and work, finds Lakshmipriya Nair
8 mins
April 2026
Translate
Change font size